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Abstract
In many fields of medicine there is a growing interest in characterizing diseases at molecular level
with a view to developing an individually tailored therapeutic approach. Metabolomics is a novel
area that promises to contribute significantly to the characterization of various disease phenotypes
and to the identification of personal metabolic features that can predict response to therapies.
Based on analytical platforms such as mass spectrometry or NMR-based spectroscopy, the
metabolomic approach enables a comprehensive overview of the metabolites, leading to the
characterization of the metabolic fingerprint of a given sample. These metabolic fingerprints can
then be used to distinguish between different disease phenotypes and to predict a drug's
effectiveness and/or toxicity.
Several studies published in the last few years applied the metabolomic approach in the field of
pediatric medicine. Being a highly informative technique that can be used on samples collected non-
invasively (e.g. urine or exhaled breath condensate), metabolomics has appeal for the study of
pediatric diseases. Here we present and discuss the pediatric clinical studies that have taken the
metabolomic approach.
Introduction
Many multifactorial diseases may have a homogeneous
clinical presentation but still be heterogeneous from a
molecular standpoint and the concept that every patient's
disease is somehow unique is gaining ground, in which
case a customized, individually-targeted therapy would be
desirable [1]. For the development of such a personalized
therapeutic approach to be feasible, diseases need to be
defined and characterized at molecular level [1]. Recent
advances in high-throughput technologies (e.g. mass
spectrometry and NMR-based spectroscopy) have enabled
the identification of biomarker profiles that characterize
disease sub-phenotypes, providing the basis for the devel-
opment of new, targeted drugs, potentially enabling us to
provide "the right therapy for the right patient" [1]. It is on
such technologies that the so-called "-omic" sciences rely,
e.g. genomics, transcriptomics, proteomics, metabo-
lomics, where these "-omic" terms have been formulated
to define approaches capable of identifying groups of
biomarkers characteristic of a particular disease within the
set of genes, mRNAs, proteins and metabolites of a given
organism [2,3].
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Metabolomics is defined as the analysis and interpreta-
tion of the global metabolic data expressing the multipar-
ametric metabolic response of living systems to genetic
modification, pathophysiological stimuli and environ-
mental influences [4,5]. Metabolomics takes a non-selec-
tive approach and, by means of a comprehensive overview
of the metabolites, enables the "metabolic fingerprint" of
a sample to be obtained [6]. Metabolomics is the latest of
the -omic sciences and it is considered the one that comes
closest to expressing phenotype, giving us the chance to
look at genotype-phenotype, as well as genotype-enviro-
type relationships. In fact, although the metabolic profile
can be seen as the ultimate expression of the information
contained in the genetic code, it is also influenced by sev-
eral factors unrelated to the genome, such as interactions
with commensal microorganisms, nutritional factors,
environmental agents, and exposure to drugs or toxic sub-
stances [3,6].
From a clinical standpoint, the metabolomic analysis has
two major potential applications. The first concerns the
early diagnosis and characterization of disease pheno-
types. Metabolomic analysis can detect a pattern of
metabolites that discriminate between groups of subjects,
enabling the metabolic characterization of a disease, or of
a disease phenotype. This is an exploratory process, since
unexpected or even unknown metabolites may turn out to
be important in this discrimination, paving the way to the
formulation of new pathophysiological hypotheses [2,4].
The second potential clinical application concerns the
identification of individual metabolomic characteristics
able to predict drug effectiveness and/or toxicity - an
approach called pharmacometabolomics, which appears
to be a promising branch of metabolomics for screening
human populations, implying the concrete possibility of
a genuinely customized approach to treatment [1]. The
concept of pharmacometabolomics has been first intro-
duced by a seminal study conducted on mice demonstrat-
ing that the hepatotoxic effects of the analgesic
paracetamol can be predicted on the basis of the pre-treat-
ment metabolomic urinary profiles [7].
Methods used in metabolomic analysis
The methods used in metabolomic analysis are generally
based on mass spectrometry or NMR-based spectroscopy,
since these techniques can handle complex biological
samples with a high sensitivity, selectivity and throughput
[8]. Mass spectrometry, usually combined with chromato-
graphic separation methods, enables the molecules in a
sample to be separated on the basis of their mass-to-
charge ratio and their representation in a spectrum [9,10].
1H-NMR spectroscopy enables the detection of almost all
proton-containing metabolites in a sample, different mol-
ecules producing different signals in the NMR spectrum
[11]. Some of the advantages of this technique are that it
is non-selective and fast, and usually demands no sample
preparation [11]. It is also non-destructive and can be
applied to the analysis of tissue samples that will subse-
quently remain available for further diagnostic analyses
[11].
A recent development is represented by the combination
of NMR and MS data, which may improve the identifica-
tion of unknown metabolites [12].
Both NMR and MS are powerful spectroscopic methods
for generating multivariate datasets: NMR and MS spectra
are highly complex and the biological information they
contain can only be extracted by applying bioinformatic
tools, such as pattern recognition methods. These are
computer-based procedures that can be classified as unsu-
pervised or supervised [13]. The unsupervised methods
reduce the complexity of the data contained in the spectra
and represent them by means of plots that the human eye
can interpret. This approach helps to identify any intrinsic
sample clustering, to see whether different groups of indi-
viduals (e.g. healthy vs ill) can be discriminated by the
characteristics of their spectra [13]. The supervised meth-
ods use a training set of samples (of known classification)
to create a mathematical model that is then used to test an
independent dataset: unlike the unsupervised methods,
they enable us to predict which group a new sample
belongs to on the strength of the characteristics of its spec-
tra [13].
Once a metabolic pattern typical of a given condition has
been characterized, the analysis may go on to identify sin-
gle biomarkers relevant to sample clustering. Fundamen-
tal support for molecular identification comes from
various on-line databases, the most comprehensive of
which is the Human Metabolomic Database [14].
Pediatric clinical studies
Metabolomic analysis can be applied to the study of bio-
logical fluids collected in non-invasive or minimally-inva-
sive ways (e.g. urine, exhaled breath condensate, blood).
Being highly informative and suitable for use on non-
invasively collected samples too, the metabolomic
approach seems particularly promising in the field of
pediatric medicine [15].
A number of recently-published studies have applied the
metabolomic approach to the pediatric population. Some
of these studies evaluated how physiological variables,
such as age or diet, can affect children's metabolomic pro-
files.
Using an NMR-based metabolomic analysis, Gu et al
demonstrated the effect of age on the urinary metabolite
profile in pre-adolescent children [16]. Likewise, a recentItalian Journal of Pediatrics 2009, 35:30 http://www.ijponline.net/content/35/1/30
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Italian study evaluated urine samples in genetically
homogeneous healthy populations, demonstrating that
the excretion of most amino acids is age-dependent [17].
Understanding the age-related characteristics of the
metabolomic profile can facilitate the interpretation of its
pathological modifications [16].
To study the effects of diet, Bertram et al [18] compared
the metabolomic urinary profiles of two groups of chil-
dren on a diet rich in milk versus meat proteins, demon-
strating that the samples could be successfully
discriminated according to the children's diet, with a sig-
nificantly greater urinary excretion of creatine in the chil-
dren on a diet rich in meat.
Other pediatric studies have focused on the metabolomic
profiles of different biofluids in the presence of patholog-
ical processes.
In one publication, metabolomics was used to study dis-
orders due to inborn errors of metabolism [19]. Mass
spectrometry is commonly used in the diagnosis of
inborn errors of metabolism to seek specific metabolites
(targeted analysis), but this study was the first to use
untargeted metabolomic analyses on plasma samples.
Investigating disorders of proprionate metabolism (meth-
ylmalonic acidemia [MMA] and propionic acidemia
[PA]), the authors found that the most important metab-
olite for discriminating between the healthy and the ill
was propionyl carnitine, which is indeed the target com-
pound for screening newborn for MMA and PA by tan-
dem-MS. This result validates the role of untargeted
metabolomic analysis in identifying biomarkers of dis-
ease. In addition, untargeted metabolomic analysis
showed that many other compounds are important in dif-
ferentiating both between healthy and ill, and between
cases of MMA and PA [19].
A Japanese group described a characteristic metabolomic
profile in the cerebrospinal fluid of children with influ-
enza-associated encephalopathy, suggesting that it might
be possible to identify specific biomarkers useful for the
early diagnosis of this disease [20].
In a study by our group [21], metabolomics was applied
to analyzing exhaled breath condensate (breathomics):
this biofluid is collected non-invasively by cooling the
exhaled air and its composition is believed to reflect that
of the airway lining fluid [21]. NMR-based metabolomic
analyses of exhaled breath condensate could clearly dis-
criminate between asthmatic and healthy children, with
95% success rate in their classification. Many authors
believe that asthma should no longer be considered a sin-
gle disease and that efforts should be made to identify the
different biochemical and inflammatory profiles behind
asthma symptoms in order to treat them with specifically-
targeted therapies [22]. The metabolomic approach may
have a role in characterizing these asthma sub-pheno-
types.
Still in the field of pediatric pulmonology, it has recently
been demonstrated that metabolomic analysis of bron-
choalveolar fluid can distinguish between different
degrees of inflammation in children with cystic fibrosis,
with the promise of identifying new biomarkers of
inflammation [23].
Metabolomic analysis has also proved useful in identify-
ing early urinary biomarkers of acute kidney injury after
cardiopulmonary bypass surgery [24]: using ultra-per-
formance liquid chromatography (UPLC)/MS based
metabolomic analyses on urine samples collected 4 and
again 12 hours after surgery, the authors were able to
identify the children that would develop acute kidney
injury over the next 3 days. From a clinical standpoint,
finding early metabolic biomarkers may improve our
understanding of the pathophysiological mechanisms
involved in acute kidney injury and enable a timely diag-
nosis of this disease after pediatric cardiac surgery.
Finally, an interesting longitudinal study applying the
metabolomic analysis to serum samples recently demon-
strated that a metabolic dysregulation precedes the onset
of the autoimmunity associated with type-1 diabetes and
the following progression to clinical diabetes [25]. This
study has potential therapeutic implications too: based on
their findings, the authors suggest that an immunomodu-
latory therapy might be more useful than immunosup-
pression in the prevention of the disease [25].
Conclusion
Metabolomics is a novel approach that promises to enable
the detection of states of disease, to stratify patients based
on biochemical profiles and to monitor disease progres-
sion. Metabolomic analysis may also be able to orient the
choice of therapy, identify responders and predict toxicity
(pharmacometabolomics), paving the way to a custom-
ized therapy.
There are many potential applications for metabolomics
in pediatric medicine, inasmuch as it is a highly informa-
tive technique that can also be used on non-invasively col-
lected samples.
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